MMP9 and ischemia: Intravenous injection of anti-HMGB1 monoclonal antibody significantly protected rats from ischemia-induced blood–brain barrier disruption, which was associated with inhibiting the expression of proinflammatory factors like iNOS, TNF-α and MMP9 and microglial cell activation [133, 157].